MTCH1 and cervical cancer: GPX4 acts as a key anti-ferroptosis enzyme in cervical cancer, and its downregulation—triggered by MTCH1 deficiency and impaired FoxO1 nuclear translocation—leads to elevated ROS and ferroptotic cell death (34).